SBG 2000-1. Individually Dose-adjusted FEC Compared to Standard FEC as Adjuvant Chemotherapy for Node Positive or High-risk Node Negative Breast Cancer. A Randomized Study by the Scandinavian Breast Group
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,535
- 主要终点
- Distant disease-free survival.
研究概览
简要总结
This is an open randomized phase III study. The primary objective of this study is to compare FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated according to the patients surface area or with doses adjusted according to leukopenia after course one in order to achieve hematological equitoxicity. The main aim of the study is to test whether chemotherapy dosage aimed at hematological equitoxicity will improve the effect of adjuvant chemotherapy.
详细描述
Group A, FECStandard(standard FEC) is given 7 courses of 5-fluorouracil-epirubicin (Farmorubicin)-cyclophosphamide with doses based on the patient's surface area. Leukocyte nadir values at day 10, 12 or 13 and 15 are measured. Dose-reductions of one step according to table 8.2.1 are performed in case of leukopenic fever or grade 4 leukopenia.
Group B FECTailored(Tailored FEC) receives course one at identical doses to group A. Leukocyte nadir values at day 10,12 or 13 and 15 are measured. Doses of subsequent courses are adjusted to achieve grade 3 leukopenia (leukocyte nadir 1.0 to 2.0) in patients experiencing only grade 0 to 2 leukopenia after course one.
Dose-reductions of one step according to table 8.2.1 are performed in case of leukopenic fever or grade 4 leukopenia .
Patients achieving only grade 0-2 leukopenia at the first course will be randomized into continued treatment at standard doses (Group A) or to doses tailored to achieve grade 3 leukopenia (Group B). The primary comparisons will be made between these two groups of patients.
Patients with grade 3-4 leukopenia after the first course not be randomized but followed according to the protocol and received treatment as group A, FECStandard.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Node positive or 2) High-risk node negative#
- •no major cardiovascular morbidity
- •female age 18-60
- •ECOG/WHO performance status <1
- •histologically proven invasive breast cancer
- •written or oral witnessed informed consent according to the local Ethics Committee requirements
- •start of adjuvant chemotherapy within 8 weeks after surgery
排除标准
- •distant metastases (M1)
- •locally advanced cancer
- •nonradically operated (positive resection margins)
- •pregnancy or lactation
- •leukocyte count < 3.5 x109 /l
- •platelets < 100 x109 /l
- •other serious medical condition
- •previous or concurrent malignancies at other sites, except basal cell carcinoma and carcinoma cervicis uteri in situ
研究组 & 干预措施
Registered
Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.
干预措施: 5-FU, epirubicin and cyclophosphamide (Drug)
Tailored
Tailored FEC (F600, E75-90, C900-1200) every 3rd week.
干预措施: 5-FU, epirubicin and cyclophosphamide (Drug)
Standard
Standard FEC (F600, E60, C600) every 3rd week.
干预措施: 5-FU, epirubicin and cyclophosphamide (Drug)
结局指标
主要结局
Distant disease-free survival.
时间窗: 5-10 years
Distant disease-free survival comparing standard and tailored arm.
次要结局
- Overall survival(5-10 years)
- Toxicity of treatment.(5-10 years)
- Regio-locally relapsed disease(5-10 years)
- Leukopenia and correlation to prognosis in distant disease-free survival.(5-10 years.)
- Effect of dose escalation of leukopenia and correlation to prognosis in distant disease-free survival.(5-10 years.)
研究者
Henrik Lindman
Senior Consultant, Ass. Professor
Uppsala University Hospital